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Primary mandibular non-Hodgkin lymphoma (NHL) and soft tissues NHL of the maxillofacial are
extremely rare representing a minimal percentage of the head and neck tumors. Two cases of bone and
soft tissue maxillofacial NHL are reported. Clinical, radiological and pathological features are described
and the therapeutic procedures are discussed accordingly. Mandibular radiologic features have been
carefully analyzed and discussed to achieve an early and accurate diagnosis avoiding improper dental
therapies.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Extra nodal non-Hodgkin lymphoma (NHL) represent 20%e30%
of all the NHL the second one occur in extra-nodal sites [1,2].
Among the NHL that occur in the oral cavity, 15e45% arise in the
maxilla and mandible [3] being the upper jaw maxilla (11%), the
mandible (8%), the palatal soft tissue (8%) and gum (7%) the most
common locations. Isolated mandibular NHL accounts for only 0.6%
of all the NHL. Soft tissues NHL of the maxillofacial area are even
more rare representing a minimal percentage of the head and neck
tumors [4]. The unique mandibular and soft localization is very rare
for the NHL and in some cases, differential diagnosis with the most
common dental lesions and other soft tissue pathologies may be
difﬁcult. Corresponding patients have to be treated withB-NHL, B-cell non-Hodgkin
needle cytology.
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[5]. It is essential to diagnose the lesion at an early stage, paying
attention to the differential diagnosis, particularly for unique
mandibular localization because clinical signs of most common
dental lesions may lead to misunderstanding of non-Hodgkin
lymphoma diagnosis [6]. There have been some reports
describing NHL [7e9] involving the mandible and soft tissue, but
not all of them clarify all clinical and imaging aspects for early
differential diagnosis. Our goal is to evaluate the clinical ﬁndings
and radiographic images of NHL with mandibular and soft tissue
localization with emphasis on differential diagnosis, in order to
achieve immediately a right diagnosis avoiding improper therapy
detrimental for prognosis.2. Cases report
2.1. Case 1
A 53-year-old woman, without any history for other pathology,
consulted our Department for left facial tumefaction with one year's
evolution, with associated dental pain without any local signs of
Fig. 1. CT in coronal projection showing mandibular tumor involvement.
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involving the horizontal branch of the mandible, without any cuta-
neous involvement. At oral examination obstruction of the entire
inferior vestibule was found. The patient didn't suffer from human
immunodeﬁciency virus infection. She did not complain of bleeding,
and no signiﬁcant clinical data were present in her clinical history.
Computerized tomography (CT) was available (Figs. 1 and 2). On
panoramic Rx, the area affected by the lesion showed osteolysis with
almost indistinct borders, root resorption of the 33, destructive tooth
decay with bone resorption at the furcation of 36; these signs in
association with the absence of inﬂammation, purulent discharge
and pain were inclined to the diagnosis of a malignant tumor.
Therefore it was decided to perform a CT scan and biopsyFig. 2. CT in axial projection showing mandibular tumor involvement.immediately. On CT images, tumor involvement of the bone marrow
cortex and of the surrounding soft tissuewas reported. Subsequently
to careful evaluation of these radiological ﬁndings, a ﬁne needle
cytology (FNC) was performed, in order to assess the proper diag-
nosis of the lesion. Based on the ﬁnal diagnosis of B-cell non-
Hodgkin lymphoma (B-NHL), she started chemotherapy according
to the R-CHOP-21 regimen that was based on the original doses used
by the GELA group and consisted of intravenous cyclophosphamide
750 mg/m, doxorubicin 50 mg/m, vincristine 1.4 mg/m (maximum
dose 2 mg), rituximab 375 mg/m on day 1, and oral prednisolone
40mg/m on days 1e5, administered every 21 days for a total of eight
cycles [10]. The patient at the end of the eight cycles will be visited
every two months in very close follow-up. To date, she has
completed 3 cycles of therapy and clinical response was good with
the disappearance of the mandibular swelling. If a recurrence or
persistence of the disease will be detected, the patient will undergo
IEV (Ifosfamide, Epirubicin, Etoposide) or DHAP (Cisplatin, Ara-C,
Dexamethasone) therapy, with subsequent mobilization and autol-
ogous stem cell [11]. Before the second scheme of chemotherapy in
case of recurrence of the tumor, a new procedure for testing tumor
stem cells sensibility to the chemotherapy will be performed.
Because of about 21 days need for test response and necessity to start
for immediate chemotherapy at the diagnosis, this method was not
used at the ﬁrst cycle.
2.2. Case 2
A 76-year-old woman presented with a left parotid swelling in
the left parotid area and a palpable ipsilateral submental lymph
node. The patient reported that she had noticed the left side of her
face growing progressively larger over the past 4 months. The pa-
tient denied any history of fever, night sweats, or signiﬁcant weight
loss. Medical and social history were not signiﬁcant. Computerized
tomography (CT) was available (Fig. 3). A ﬁne needle cytology
(FNC), performed on the periparotideal mass diagnosed an NHL,
and the diagnosis was conﬁrmed by the following surgical biopsy.
Based on the ﬁnal diagnosis of B-cell NHL the patient was treatedFig. 3. CT in axial projection showing the soft tissue mass in the periparotideal area.
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tine, and prednisone) for 6 cycles. At the end of the six cycles will be
visited every two months in very close follow-up. To date, she has
completed 4 cycles of therapy and clinical response was good with
the disappearance of the parotid swelling. If a recurrence or
persistence of the disease will be detected, the patient will undergo
IEV (Ifosfamide, Epirubicin, Etoposide) or DHAP (Cisplatin, Ara-C,
Dexamethasone) therapy, with subsequent mobilization and
autologous stem cell.
3. Results
3.1. Radiographic ﬁndings
Referring to case 1 it is not simple to make the right diagnosis of
tumor on panoramic images. Multiple and different are the radio-
graphic signs of tumor. For the unique mandibular localization,
these ﬁndings could be an ill-deﬁned radiolucency of the mandible
indicating bone destruction, displacement of the teeth in an
occlusal direction, loss of the mandibular canal wall, and loss of the
crypt cortex of the unerupted teeth. Sometimes it is possible to ﬁnd
a loss of the lamina dura and widening of the periodontal ligament
space that could suggest the presence of the tumor [3,12]. In our
case there were osteolysis with almost undeﬁned borders, root
resorption of the 33, destructive tooth decay with rarefaction of the
furcating of 36: these signs in association with the absence of
inﬂammation, purulent discharge and pain were suggestive for a
malignant tumor. CT showed a bone marrow involvement by tu-
mor, the cortical bonewas destroyed and the tumor had extensively
spread to the surrounding soft tissue and the sub-mandibular
spaces. MRI depicted the tumor extent more clearly than CT scan
[12]. Immediately after careful radiologic imaging evaluation,
cytologic (FNC) and histologic (biopsy) exams were carried out. As
for the ﬁrst case, the PET/CT examination showed an increase in
volume of the left periparotideal soft tissue presenting a homoge-
neous solid nodule (maximum length 18 mm) (Figs. 3 and 4).
Latero-cervical lymphadenopathies were not found. Ct scan is
useful for parotideal and extraparotideal tumor diagnosis. LogginsFig. 4. PET/CT soft tissue mass in the periparotideal area.et al. [13] showed several trends in the majority of patients with
parotid lymphoma, including bilateral parotid involvement, mul-
tiple masses, lymphadenopathy, and an ill-deﬁned tumor. The
beneﬁts of CT imaging include increased accessibility, lower cost,
and faster results compared withMRI. When reviewing anMRI, it is
important to accurately differentiate between extraparotideal and
intraparotideal location of the tumor to determine spatial rela-
tionship to a possible involvement of the facial nerve. Radiographic
features that may suggest perineural involvement include
enlargement or bony erosion of skull base neural foramina, oblit-
eration of perineural fat planes, and nerve enlargement or
abnormal contrast enhancement [14]. Immediately after careful
radiologic imaging evaluation, ﬁne needle cytology (FNC) and his-
tologic (biopsy) [15] exams were carried out as previously
described [16e20].
3.2. Cytological and histological ﬁndings
Histopathology, immunohistochemistry, immunophenotyping,
and genetic studies help to make non-Hodgkin lymphoma diag-
nosis, in order to direct a speciﬁc regimen of therapy. Non-Hodgkin
lymphoma usually express pan B-cell markers such as CD19, CD20,
CD75, CD79a, and CD22; but may lack one or more of these [21,22].
Surface and or cytoplasmic immunoglobulins (IgM > IgG > IgA) can
be demonstrated in 50e75% of cases [22]. According to the cyto-
logical and FC features (Fig. 5), in the ﬁrst case a diagnosis of non-
Hodgkin B-cell lymphoma, possibly a mantle cell lymphoma was
performed. The subsequent histological examination conﬁrmed the
diagnosis of mantle cell non-Hodgkin lymphoma. In the second
case FNC also indicated a lymphoproliferative process. The
removed fragments showed a histological diffuse large cell lym-
phoma (Fig. 6) that was positive for CD20, CD43, MUM1 and CD138.
The ﬁnal diagnosis was diffuse large non-Hodgkin lymphoma
(DLBCL).
4. Discussion
Non-Hodgkin lymphoma can involve any site in the extra-cranial
head and neck [4]. Many authors support differential diagnosis of the
tumor involving the mandible including multiple myeloma, Ewing
sarcoma, Langerhans cell histiocytosis, leukemia, osteosarcoma,
bone metastasis, and osteomyelitis [9,22e25]. Only when there is a
high degree of suspicion could the patient with non-Hodgkin lym-
phoma in the head and neck be correctly diagnosed by carefulFig. 5. Cytological features of case n. 1 showing a monomorphous population of
atypical lymphocytes (Diff-Quik stain 430).
Fig. 6. Histological features of case n. 2 showing a diffuse large cell
lymphoma (haematoxylin-eosin 430).
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propriate invasive dental procedures and proceeding immediately
with biopsy [26,27]. Because NHL involving the mandible as unique
localization is very uncommon, its imaging ﬁndings have not been
well covered in the literature. In the case of the soft tissue, peripar-
otideal NHL, FNC orientated the diagnosis that was conﬁrmed by the
following histological control. Our goal is to show how an immediate
differential diagnosis, even if of only probability on panoramic X-rays
and clinical ﬁndings is possible. In fact, this lesion should not be
confused with the more common dental diseases (abscess, perios-
titis, granuloma, periodontitis), whose treatment, commonly per-
formed without any cytological and histological examinations, could
only worsen the prognosis for the diffusion of the tumor with
invasive dental treatment. Unique mandibular localization of non-
Hodgkin lymphoma much complicate differential diagnosis with
dental related pathology. Because panoramic X-ray of the jaws is the
most common and often the unique Rx performed in dental pa-
thologies, it is important carefully to analyze the imaging signs useful
for a correct diagnosis not only for immediate proper therapy, but
above of all to avoid invasive dental therapies detrimental for
prognosis and often without any chances to be corrected by patho-
logical ﬁndings because usually not performed in common dental
cares. In these unlucky cases, only ineffectiveness of dental therapies
with clinical worsening of local condition may lead to a biopsy with
correct diagnosis. Furthermore, three factors may complicate dif-
ferential diagnosis in this case: 1) common association with dental
related pathologies for patients with jaw's tumors for poor oral hy-
giene and difﬁculties of teeth brushing for gingival bleeding and pain
and 2) unique localization of the NHL. For the ﬁrst aspect situation
may be complicated by the association of the neoplastic lesion with
dental related pathologies in the same site. For the second aspect it is
evident that a detection of other lesions in other districts may
facilitate a correct diagnosis suggesting the opportunity of per-
forming biopsies and histological analysis in one or both sites; 3)
third factor often complicating immediate right diagnosis are the
normal results of common hematological exams with a normal
lymphocytic asset. For all these reasons, it is important to investigate
all the pathological signs on the radiologic imaging, particularly on
panoramic Rx of the jaws because this is the ﬁrst and often the only
survey instrument performed by dentists before dental therapies.
Because the ﬁrst clinical evaluation of these patients is usually per-
formed in dental ofﬁces, it is essential to clarify all clinical and X-ray
exams particularly for panoramic X-ray of the jaws, commonly the
only exams performed for dental cares. At this stage it is important toimmediately distinguish between common dental disease and ma-
lignant osteolytic lesion only on the support of clinical ﬁndings and
panoramic X-ray because these are the only information available by
dental doctors for suspected dental diseases. In case of soft tissue
NHL, along with the deﬁnition of the integrity of the parotid by
imaging studies, an FNC is routinely obtained. In case of a parotid
mass of unknown etiology, physician can rule out a variety of
pathologic entities with the completion of an FNC, particularly in
conjunctionwith ﬂow cytometry and immunophenotyping [28e32].
4.1. Radiographic ﬁndings
Imaging diagnosis, especially initial diagnosis using panoramic
images was considered to be very important. It has been reported
that non-Hodgkin lymphoma involving the jaws shows ill deﬁned
bone destruction on conventional images. Therefore, ill deﬁned
bone destruction may not be a common panoramic ﬁnding of this
tumor involving the mandible [12,25]. Careful observation was
considered to be necessary when interpreting panoramic images,
because they might demonstrate bone destruction by malignant
neoplasm in case of non-Hodgkin lymphoma in particular areas
[33]. In our study, such a ﬁnding was perceptible on panoramic
images. Hicks et al. [34] evaluated histopathology ﬁndings of pri-
mary NHL of the bone and reported that osteoclasts formed tunnels
penetrating the cortex and that the tumor spread out from the
marrow to the surrounding soft tissue through these cortical
tunnels.
Radiological semiology is poor but quite suggestive: Martinelli-
Klay et al. [35] showed howmicro lacunae could, in rare cases, give
the bone a moth eaten or honeycomb aspect. Imaging may also
reveal pathological fracture or osteolysis with orwithout associated
condensation of neighboring soft tissue or periosteal thickening.
Based on our results, the characteristic CT ﬁnding is that the
cortical bone destructionwas mild in relationwith the extension of
bone marrow and soft tissue involvement by the tumor. Yamada
[36] and Buric [37] reported widening of the mandibular canal and
mental foramen as ﬁndings suggesting non-Hodgkin lymphoma. As
we did not observe these features in the present series, the pres-
ence of such features should anyway be carefully examined. Mat-
sumoto et al. [38] evaluated CT ﬁndings of non-Hodgkin lymphoma
of the maxillary sinus. They reported that the tumor extended
beyond the bony wall without bone destruction and that this
ﬁnding was useful in differentiating non-Hodgkin lymphoma from
squamous cell carcinoma of themaxillary sinus. Imaizumi et al. [12]
reported that MRI ﬁndings were superior to CT in evaluating the
extent of osseous and soft tissue involvement by the tumor.
Therefore, we can uphold that the panoramic radiograph is
almost useful for early diagnosis; MRI appears to be the best
investigation for the ability to view the progress of the lesion in the
soft tissues, which fails at high resolution CT. Panoramic images
were considered an important investigation particularly at an early
stage of diagnosis, because it allows to visualize and detect the ﬁrst
signs of malignancy (cortical destruction, teeth extrusion, peri-
odontal widening). Following this radiographic examination, CT
may conﬁrm these ﬁndings. While, for the soft tissue periparotideal
localization, initial evaluation should include CT or MRI to deter-
mine location, shape, and size. The presence of extraglandular
involvement, cervical lymphadenopathy, and the relationship to
vital structures are also readily assessed with imaging [39]. CT and
MRI have been described to be equally effective when evaluating
for parotid tumor location, margin, and inﬁltration. MRI is the
preferred imaging modality at our institution, owing to its superior
soft tissue contrast. Although MRI has the ability to deﬁne the in-
ternal architecture of complex masses, it is not histologically spe-
ciﬁc [40]. PET scanning is also frequently used in the management
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to provide a means for surveillance within the post-treatment
course. PET has 80% sensitivity and 90% speciﬁcity in the identiﬁ-
cation of malignancy [14]. As for the prognosis, patients with NHL
have variable clinical courses and prognosis depending on many
clinical, morphological, phenotypic, and genetic parameters [27].
Agrawal [41] and Ramani [42] reported that the prognosis of the
disease is good with a maximum of 5-year survival rate in 30% of
cases after therapy. The disease may occasionally progress into a
diffuse patternwith cutaneous nodules and plaques which undergo
blast transformation or rarely turn into leukemia. Beal et al. [43] in
a long-term follow-up of 82 patients with primary bone lymphoma,
have found that patient's prognosis is excellent, with a 5-year
survival rate of 95%. Mnejja [37] and Kemp [4] showed that prog-
nosis is poorer in maxillary non-Hodgkin lymphoma than in mouth
cavity soft tissue involvement. In single-focus lesions, prognosis is
relatively favorable, with fairly long survivorship and more than
60% remission at 5 years. The prognosis of soft tissue of the peri-
parotideal gland will depend on the histology, staging, and risk
factors. Diffuse large B-cell NHL are characterized by fast and
inﬁltrative growth. Prognosis additionally depends on staging
evaluation, which is accomplished via PET-CT and bone marrow
biopsy to determine the extent of the disease [44e45]. In case of
macroscopic relapse of the tumor, a new method of tumor stem
cells sensibility guided chemotherapy can be performed. With this
new technique it will be possible to grow tumor stem cells in vitro,
testing speciﬁc sensitivity to different drugs and gaining useful
indications for speciﬁc chemotherapy [10,11]. Therefore, we can
state that the prognosis is deﬁnitely inﬂuenced by radiographic
signs of Orthopantomogram and CT, as well as the degree of inﬁl-
tration and presence of histologic markers. In conclusion, the main
purpose of this article is to stress the importance of early diagnosis
to ensure appropriate treatment, to improve prognosis, and quality
of life. NHL in bone and soft tissue may be effectively managed by
chemotherapy alone. So, imaging ﬁndings of NHL involving the
mandible could be different for each case but a careful observation
is considered to be necessary when interpreting conventional im-
ages, because they might demonstrate bone involvement by the
tumor. Clinical examination of a periparotidea soft tissue NHL may
be indistinguishable from other benign or malignant swellings and
should always be part of the differential diagnosis. Imaging may
also provide information, that help to differentiate these entities
from parotideal malignant tumors. Treatment can then be tailored
to the speciﬁc grade and histological type via chemotherapy,
radiotherapy, or both, and prognosis is generally good.
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